Table 1.
Sample characteristics (N = 194), by randomization group/baseline PEth, n (%)
| Randomization group | Baseline PEth | Total (N = 194) | |||
|---|---|---|---|---|---|
|
|
|
||||
| Naltrexone (n = 96) | Placebo (n = 98) | PEth+ (n = 46) | Peth− (n = 148) | ||
| Age | |||||
| Mean(SD) | 47.7(8.5) | 48.9(8.9) | 47.8(7.6) | 48.5(9.1) | 48.3(8.7) |
| Race/Ethnicity | |||||
| White | 3(3.1) | 5(5.1) | 3(6.5) | 5(3.4) | 8(4.1) |
| Black | 81(84.4) | 80(81.6) | 40(87.0) | 121(81.8) | 161(83.0) |
| Hispanic | 11(11.5) | 11(11.2) | 3(6.5) | 19(12.8) | 22(11.3) |
| Other | 1(1.0) | 2(2.0) | 0(0.0) | 3(2.0) | 3(1.6) |
| Marital Status | |||||
| Single | 80(83.3) | 83(84.7) | 38(82.6) | 135(84.5) | 163(84.0) |
| In relationship | 16(16.7) | 15(15.3) | 8(17.4) | 23(15.5) | 31(16.0) |
| Education | |||||
| Less than high school | 40(41.7) | 44(44.9) | 18(39.1) | 66(44.6) | 84(43.3) |
| High school graduate | 38(39.6) | 28(28.6) | 19(41.3) | 47(31.8) | 66(34.0) |
| Some college/college graduate | 18(18.7) | 26(26.5) | 9(19.6) | 35(23.6) | 44(22.7) |
| Employment | |||||
| Employed | 11(11.5) | 9(9.18) | 5(10.9) | 15(10.1) | 20(10.3) |
| Not employed | 85(88.5) | 89(90.8) | 41(89.1) | 133(89.9) | 174(89.7) |
| Liver disease | |||||
| Yes | 18(18.7) | 18(18.4) | 6(13.0) | 30(20.3) | 36(18.5) |
| Diabetes | |||||
| Yes | 8(8.3) | 12(12.2) | 6(13.0) | 14(9.4) | 20(10.3) |
| BMI | |||||
| Mean(SD) | 30.1(8.5) | 30.4(8.2) | 27.7(6.9) | 31(8.6) | 30.3(8.3) |
| Self-reported drinks/week | |||||
| Median(IQR) | 43(46) | 42(67) | 59(56) | 39(58) | 43(58) |
Note. PEth+ or PEth− was based on the baseline PEth value using 50ng/ml as the cut-off. IQR = interquartile range. Chi-square test (or t-test for continuous variables) showed no significant differences in demographics and health conditions between PEth+ and PEth− groups, except a significantly higher BMI for PEth− group (t = 2.40, df = 192, p < .05).